Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eptinezumab

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

- PMLiVE

Lundbeck to cut 1,000 jobs in major restructure

Losses will be felt in its headquarter functions and commercial operations

- PMLiVE

Rebuffed Horizon tries to replace Depomed board members

But firm says latest deal 'significantly undervalues' Depomed

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

Allergan logo

Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

Company will add Kythera’s double chin therapy Kybella to its portfolio

- PMLiVE

Schultz takes Lundbeck helm after leaving Novo Nordisk

Former executive left Danish firm just days ago

Teva Pharma logo

Teva starts M&A push with $3.5bn Auspex buy

Aims to diversify business away from dependency on Copaxone

- PMLiVE

Brintellix first antidepressant with cognition claim in Europe

Trial found it performed better than Lilly’s rival Cymbalta

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

- PMLiVE

Medical device M&A hit ‘all-time high’ in 2014

Deals last year were led by Medtronic’s acquisition of Covidien

- PMLiVE

NICE backs drug to cut alcohol consumption

Final guidance for Lundbeck’s Selincro for use on NHS in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links